VNDA
Vanda Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.12
+0.20%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.07
From 52W high−46.44%
Volume1.65M
Market cap$309.57M
P/E (TTM)—
P/S (TTM)1.4x
Div yield—
Key dataSep 18, 2026
Open
$5.07
From 52W high
−46.44%
Volume
1.65M
Market cap
$309.57M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
43.0
MomentumView details →
1D Return
+0.20%
YTD Return
−42.65%
SummaryUpdated Jun 1, 2026
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a biopharmaceutical company founded in 2002 and headquartered in Washington, D.C. The company went public in April 2006 and focuses on developing and commercializing therapies to address high unmet medical needs, particularly in the areas of sleep disorders, psychiatric conditions, and other central nervous system disorders. Vanda has successfully brought several products to market and maintains a robust pipeline of investigational therapies across multiple therapeutic areas.
Similar companies
Latest newsMore news →
Vanda Pharmaceuticals Inc.'s Board of Directors declared a dividend distribution of one Right for each outstanding share of Common Stock to stockholders of record as of April 29, 2024, with each Right entitling the holder to purchase one one-thousandth of a share of Series A Junior Participating Preferred Stock at an exercise price of $25.00.15d agoVanda Pharmaceuticals announced that the European Commission granted Orphan Designation to its investigational drug imsidolimab for the treatment of Generalized Pustular Psoriasis, based on a positive opinion from the EMA's Committee for Orphan Medicinal Products.27d ago